Alnylam pharmaceuticals reports second quarter 2023 financial results and highlights recent period activity

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today reported its consolidated financial results for the second quarter ended june 30, 2023 and reviewed recent business highlights. “the second quarter of 2023 was a very productive one at alnylam, with commercial execution delivering 43% year-over-year growth in net product revenues, supported by the strong ongoing launch of amvuttra,” said yvonne greenstreet, mbchb, chief.
ALNY Ratings Summary
ALNY Quant Ranking